Understand the source comparison
VIP Research Comparison Table
Understanding how VIP compares to related neuropeptides and administration variables helps researchers design protocols with higher replication probability. Receptor Specificity VPAC1, VPAC2 VPAC1, VPAC2, PAC1 Secretin receptor (class B GPCR) VIP offers select
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how VIP compares to related neuropeptides and administration variables helps researchers design protocols with higher replication probability.
- Receptor Specificity
- VPAC1, VPAC2
- VPAC1, VPAC2, PAC1
- Secretin receptor (class B GPCR)
- VIP offers selective VPAC targeting without PAC1 cross-reactivity
- Plasma Half-Life
- 1–2 minutes
- 5–10 minutes
- 2–3 minutes
- All exhibit rapid degradation requiring frequent dosing
- Anti-Inflammatory Potency
- Moderate (IC50 ~10 nM for TNF-α)
- High (IC50 ~2 nM for TNF-α)
- Low (minimal direct immune effect)
- PACAP shows stronger direct immune modulation
- CNS Penetration
- Limited (~5% BBB crossing)
- Negligible (<1% BBB crossing)
- Limited (~8% BBB crossing)
- Intranasal route improves but doesn't solve CNS access
- Stability Post-Reconstitution
- 7–10 days at 2–8°C
- 14–21 days at 2–8°C
- 10–14 days at 2–8°C
- VIP requires faster use than structurally similar peptides
- Research Application Focus
- Autoimmune, CIRS, pulmonary hypertension
- Inflammatory models, immune cell studies
- Neuroprotection, stress response
- Pancreatic function, secretion studies
- VIP's VPAC selectivity makes it ideal for immune-focused protocols